RET and non-small cell lung carcinoma: The LIBRETTO-001 trial was a phase I/II, single-arm, open-label study of selpercatinib in patients with RET-fusion-positive NSCLC, including 69 treatment-naïve patients and 247 patients previously treated with platinum-based chemotherapy.